Signs of a Strong Head Start for Wegovy Tablets
As we move through the first month of real-world utilization, Wegovy tablets are showing unexpectedly strong uptake for obesity – getting a head start on the anticipated arrival of Lilly’s orforglipron. Early utilization data suggest Wegovy in an oral form might be carving out meaningful space in obesity, defying initial skepticism.
The Skepticism
When enthusiasm for Wegovy tablets first surfaced, some observers questioned whether patients would embrace this oral GLP-1 receptor agonist for weight management. After all, oral semaglutide (Rybelsus) has been on the market for type 2 diabetes at lower doses for years, and has had great success. Many clinicians and patients found that the Rybelsus tablet was inconvenient because of tight constraints on the timing of doses well before the first meal of the day. Speculation was that the novelty of an oral format alone wouldn’t be enough to have a big impact.
But early evidence suggests otherwise. Early data indicate that clinicians are prescribing Wegovy tablets for patients at a rate that matches early uptake for tirzepatide in obesity. It may be that this tablet launch will broadened conversations about obesity management itself, bringing new patients into care who might not otherwise have engaged with treatment.
A Hiccup for Orforglipron
Meanwhile, orforglipron’s regulatory timeline got a little delay. When the company submitted orforglipron for FDA approval, Lilly tapped into an expedited review pathway called the Commissioner’s National Priority Review Program. However, the expectation for quick and easy approval recently slipped a little when Reuters reported a delay in the FDA target date for action to April 10.
Right now, this delay is small. But if other delays ensue it could extend the head start for Wegovy tablets in clinical practice. Given the chaos at FDA right now, further delays are hardly out of the question.
Early Days
So if early patterns hold, oral Wegovy might do more than “borrow” demand from injectables. It may well expand the treatable population, while enjoying a head start on orforglipron. The potential to serve a larger population is good news – both for patients and for a field long constrained by under-utilization and poor adherence over time.
Click here for more on the early uptake of Wegovy tablets and here for reporting on the regulatory delay for orforglipron.
Tortoise and the Hare, illustration by Arthur Rackham / Wikimedia Commons
Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.
January 20, 2026
